Pfizer closes Ferrosan Consumer Health deal
This article was originally published in Scrip
Pfizer says it has closed its purchase of the consumer healthcare firm, Ferrosan. The US firm announced its intention to buy the Danish company earlier this year (scripintelligence.com, 7 February 2011). Ferrosan's business includes dietary supplements and lifestyle products and should broaden Pfizer's own portfolio. "Ferrosan Consumer Health's innovative products and geographic footprint are a strong fit for our business," said Paul Sturman, president of Pfizer Consumer Healthcare. The financial details of the deal have not been disclosed.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.